Cargando…
Children with Steroid Dependent Nephrotic Syndrome: Rituximab or Tacrolimus? It’s All in the Timing
Autores principales: | Qader, Md Abdul, Vivarelli, Marina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10496064/ https://www.ncbi.nlm.nih.gov/pubmed/37705906 http://dx.doi.org/10.1016/j.ekir.2023.07.016 |
Ejemplares similares
-
Long-Term Efficacy and Safety of Rituximab Versus Tacrolimus in Children With Steroid Dependent Nephrotic Syndrome
por: Basu, Biswanath, et al.
Publicado: (2023) -
Circulating Anti-Rituximab Antibodies Do Not Affect Response to Rituximab in Steroid-Dependent Nephrotic Syndrome
por: Angeletti, Andrea, et al.
Publicado: (2022) -
Experience with tacrolimus in children with steroid-resistant nephrotic syndrome
por: Butani, Lavjay, et al.
Publicado: (2009) -
Rituximab therapy in adults with steroid-dependent nephrotic syndrome
por: Zhong, Hongzhen, et al.
Publicado: (2019) -
Comparison of rituximab, cyclophosphamide, and tacrolimus as first steroid-sparing agents for complicated relapsing/steroid-dependent nephrotic syndrome in children: an evaluation of the health-related quality of life
por: Wang, Li, et al.
Publicado: (2022)